EUS has been implicated in immune therapies by administering TNFerade, an immunotherapeutic agent that exhibits its effect through transporting human tumor necrosis factor alpha gene to the cancer cells using replication-deficient adenovirus that has a tumor necrosis factor alpha complementary DNA ligated to the Egr-1 radiation-inducible promoter gene integrated into its genome (42). Here, TNF is linked to cancer.